Trial Profile
A Phase Ib/II Clinical Evaluation of the Safety of Combining the mTOR inhibitor Everolimus with 5-Azacitidine in AML
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Everolimus (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Biomarker
- 08 Jun 2016 Status changed from recruiting to completed.
- 14 Jul 2011 New trial record